Lilly

[Anonymous]

Lilly, Acrux get FDA OK for topical testosteroneRelated stories

AU:ACR ARUXF SYDNEY (MarketWatch) -- U.S. drug maker Eli Lilly and Co. /quotes/comstock/13*!lly/quotes/nls/lly (LLY 34.17, +0.09, +0.26%) and Acrux Ltd. /quotes/comstock/22x!e:acr (AU:ACR 3.36, +0.28, +9.09%) /quotes/comstock/11i!aruxf (ARUXF 3.38, +0.28, +9.03%) said Wednesday that the U.S. Food and Drug Administration has approved Axiron, a topical solution for testosterone replacement therapy in men. Shares of Acrux jumped 8.4% in Sydney trading following the announcement

 

[Anonymous]

We are going to kill you guys. Bye bye who are you? Another weak company gets eliminated.

 

[Anonymous]

We are going to kill you guys. Bye bye who are you? Another weak company gets eliminated.

Just like you took over the PDE5 market right? Please. You product delivery system sucks and this is a loser product. You also might want to focus on the company with 78% market share genius and thats not us. Either way, we established our niche and thats all we need.

 

[Anonymous]

Dont be so sure. Lilly will take share from all in the class. Agel is most vulnerable as the market leader but Testim could really get hurt. Besides, with SW running your managed care I am sure he will be able to blunt Lilly's impact on testim reimbursement. Ha Ha Dont be surprised if you are not covered on a couple of more formularies. Lilly is very formidable in the MC arena.

 

[Anonymous]

Although the fig tree shall not blossom, neither shall fruit be in the vines;
the labour of the olive shall fail, and the fields shall yield no meat;
the flock shall be cut off from the fold, and there shall be no herd in the stalls: Yet I will rejoice in the LORD, I will joy in the God of my salvation.